MA58093B1 - Nouveaux analogues d'insuline et leurs utilisations - Google Patents

Nouveaux analogues d'insuline et leurs utilisations

Info

Publication number
MA58093B1
MA58093B1 MA58093A MA58093A MA58093B1 MA 58093 B1 MA58093 B1 MA 58093B1 MA 58093 A MA58093 A MA 58093A MA 58093 A MA58093 A MA 58093A MA 58093 B1 MA58093 B1 MA 58093B1
Authority
MA
Morocco
Prior art keywords
insulin analogues
new insulin
analogs
diabetes
relates
Prior art date
Application number
MA58093A
Other languages
English (en)
Inventor
Peter Madsen
Thomas Børglum KJELDSEN
Mathias Norrman
Jeppe Sturis
Helle Birk Olsen
Frantisek Hubalek
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA58093B1 publication Critical patent/MA58093B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention s'inscrit dans le domaine thérapeutique des médicaments pour traiter des états médicaux associés au diabète. Plus spécifiquement, l'invention concerne des analogues d'insuline de l'insuline humaine. L'invention concerne des compositions pharmaceutiques comprenant de tels analogues d'insuline et les utilisations de tels analogues pour le traitement ou la prévention d'états médicaux associés au diabète.
MA58093A 2019-12-11 2020-12-10 Nouveaux analogues d'insuline et leurs utilisations MA58093B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11
EP20820432.1A EP4073097B1 (fr) 2019-12-11 2020-12-10 Nouveaux analogues d'insuline et leurs utilisations
PCT/EP2020/085541 WO2021116292A1 (fr) 2019-12-11 2020-12-10 Nouveaux analogues de l'insuline et leurs utilisations

Publications (1)

Publication Number Publication Date
MA58093B1 true MA58093B1 (fr) 2024-09-30

Family

ID=68886882

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58093A MA58093B1 (fr) 2019-12-11 2020-12-10 Nouveaux analogues d'insuline et leurs utilisations

Country Status (29)

Country Link
US (3) US11498951B2 (fr)
EP (2) EP4480492A3 (fr)
JP (2) JP6995284B2 (fr)
KR (1) KR102427426B1 (fr)
CN (1) CN114787184A (fr)
AR (1) AR120717A1 (fr)
AU (1) AU2020402135A1 (fr)
BR (1) BR112022009510A2 (fr)
CA (1) CA3159114A1 (fr)
CL (1) CL2023000086A1 (fr)
CO (1) CO2022007273A2 (fr)
DK (1) DK4073097T3 (fr)
ES (1) ES2985989T3 (fr)
FI (1) FI4073097T3 (fr)
HR (1) HRP20241042T1 (fr)
HU (1) HUE067827T2 (fr)
IL (2) IL292762B2 (fr)
LT (1) LT4073097T (fr)
MA (1) MA58093B1 (fr)
MX (2) MX2022006251A (fr)
MY (1) MY208364A (fr)
PE (1) PE20221260A1 (fr)
PH (1) PH12022551094A1 (fr)
PL (1) PL4073097T3 (fr)
PT (1) PT4073097T (fr)
RS (1) RS65822B1 (fr)
SI (1) SI4073097T1 (fr)
TW (1) TWI773009B (fr)
WO (1) WO2021116292A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
MA58093B1 (fr) * 2019-12-11 2024-09-30 Novo Nordisk A/S Nouveaux analogues d'insuline et leurs utilisations
KR102980610B1 (ko) 2021-10-22 2026-06-19 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5382574A (en) 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
ATE317443T1 (de) 1996-12-20 2006-02-15 Novo Nordisk As N-terminal verlängerte proteine exprimiert in hefe
CA2283705A1 (fr) 1997-03-20 1998-10-01 Novo Nordisk A/S Cristaux d'insuline depourvus de zinc et utiles dans des compositions pour les voies respiratoires
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
EP1863840A1 (fr) 2005-03-18 2007-12-12 Novo Nordisk A/S Insuline monocatenaire pegylee
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
EP1996709A2 (fr) 2006-03-13 2008-12-03 Novo Nordisk A/S Insuline monocaténaire acylée
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
WO2009022006A1 (fr) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulines avec une fraction acyle comprenant des unités répétitives d'alkylène glycol contenant des acides aminés
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2262539B1 (fr) 2008-04-01 2015-07-15 Novo Nordisk A/S Conjugués insuline-albumine
EP2448962B1 (fr) 2009-06-30 2016-10-19 Novo Nordisk A/S Dérivés d'insuline
CN102665676B (zh) 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
EP2585484A1 (fr) 2010-06-23 2013-05-01 Novo Nordisk A/S Analogues de l'insuline contenant des liaisons disulfures supplémentaires
WO2012015691A2 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Lectines recombinées, lectines à site de liaison modifié et leurs utilisations
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
EP2720711A1 (fr) 2011-06-15 2014-04-23 Novo Nordisk A/S Insulines à substitutions multiples
EP2771026A4 (fr) 2011-10-27 2015-08-05 Univ Case Western Reserve Formulations d'analogue d'insuline agissant rapidement, ultra-concentrées
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3341401A1 (fr) 2015-08-25 2018-07-04 Novo Nordisk A/S Nouveaux dérivés de l'insuline et leurs utilisations médicales
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
WO2019125879A2 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
MA58093B1 (fr) * 2019-12-11 2024-09-30 Novo Nordisk A/S Nouveaux analogues d'insuline et leurs utilisations

Also Published As

Publication number Publication date
EP4480492A3 (fr) 2025-03-19
US11498951B2 (en) 2022-11-15
PE20221260A1 (es) 2022-08-16
EP4073097A1 (fr) 2022-10-19
HRP20241042T1 (hr) 2024-11-08
SI4073097T1 (sl) 2024-09-30
JP2021091685A (ja) 2021-06-17
AR120717A1 (es) 2022-03-09
TWI773009B (zh) 2022-08-01
IL319162A (en) 2025-04-01
HUE067827T2 (hu) 2024-11-28
US20240141011A1 (en) 2024-05-02
US12122818B2 (en) 2024-10-22
EP4480492A2 (fr) 2024-12-25
CO2022007273A2 (es) 2022-08-19
MY208364A (en) 2025-05-01
DK4073097T3 (da) 2024-08-19
AU2020402135A1 (en) 2022-06-02
US12152063B2 (en) 2024-11-26
JP6995284B2 (ja) 2022-01-14
MX2023000398A (es) 2023-02-02
US20210179685A1 (en) 2021-06-17
PL4073097T3 (pl) 2024-10-28
IL292762B2 (en) 2025-10-01
KR20210141748A (ko) 2021-11-23
RS65822B1 (sr) 2024-09-30
WO2021116292A1 (fr) 2021-06-17
FI4073097T3 (fi) 2024-08-13
JP2021119193A (ja) 2021-08-12
CN114787184A (zh) 2022-07-22
IL292762B1 (en) 2025-06-01
US20230192801A1 (en) 2023-06-22
ES2985989T3 (es) 2024-11-08
TW202136289A (zh) 2021-10-01
CL2023000086A1 (es) 2023-08-04
PT4073097T (pt) 2024-08-16
IL292762A (en) 2022-07-01
KR102427426B1 (ko) 2022-08-01
EP4073097B1 (fr) 2024-07-03
PH12022551094A1 (en) 2024-06-24
MX2022006251A (es) 2022-06-22
LT4073097T (lt) 2024-09-10
BR112022009510A2 (pt) 2022-08-16
CA3159114A1 (fr) 2021-06-17

Similar Documents

Publication Publication Date Title
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
GB0410266D0 (en) Treatment of apoptosis
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
Mameli et al. Bromelain: An overview of applications in medicine and dentistry
MA57226B1 (fr) Méthodes de traitement d'une splénomégalie
EA201300314A1 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP2017514911A5 (fr)
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
DE602005009176D1 (de) Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin
MY208364A (en) Novel insulin analogues and uses thereof
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
Yingsakmongkol et al. Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
MA53898B1 (fr) Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
EP4501918A4 (fr) Dérivé de 3-phénylisoxazole et composition pharmaceutique pour prévenir ou traiter une maladie oculaire le contenant en tant que principe actif
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
MA71282A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine
EA028540B1 (ru) Применение адсорбированного гомогената трутневого расплода и витамина dили витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний
RU2585097C1 (ru) Способ лечения хронического панкреатита
RU2025131205A (ru) Производные имидазотриазина в качестве модуляторов il-17
MX2021003143A (es) Composicion de anticuerpo anti-tfpi altamente eficaz.